Email this article BONE METABOLIC DETERMINANTS OF THE EFFICACY OF ZOMETA IN PATIENTS WITH DISSEMINATED PROSTATE CANCER
- Authors: Alyaev Y.G.1, Vinarov A.Z.1, Shelepova V.M.2, Demidko Y.L.1
-
Affiliations:
- Clinic of Urology, I.M. Sechenov Moscow Medical Academy
- N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
- Issue: Vol 5, No 3 (2009)
- Pages: 48-52
- Section: PROSTATE CANCER
- Published: 30.09.2009
- URL: https://oncourology.abvpress.ru/oncur/article/view/262
- DOI: https://doi.org/10.17650/1726-9776-2009-5-3-48-52
- ID: 262
Cite item
Full Text
Abstract
The efficacy of Zometa has been evaluated in the treatment of patients with disseminated prostate cancer. The use of Zometa as an inhibitor of bone resorption in the presence moderate changes in the activity of bone resorptive processes has shown the highest survival rates.
About the authors
Yu. G. Alyaev
Clinic of Urology, I.M. Sechenov Moscow Medical Academy
Email: alexpopko@yandex.ru
Russian Federation
A. Z. Vinarov
Clinic of Urology, I.M. Sechenov Moscow Medical Academy
Author for correspondence.
Email: alexpopko@yandex.ru
Russian Federation
V. M. Shelepova
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Email: alexpopko@yandex.ru
Russian Federation
Yu. L. Demidko
Clinic of Urology, I.M. Sechenov Moscow Medical Academy
Email: alexpopko@yandex.ru
Russian Federation
References
Supplementary files
